MDM2 AND P53 INTERACTION INHIBITORS Russian patent published in 2013 - IPC C07D401/12 C07D413/14 C07D487/04 A61K31/4439 A61K31/4709 A61K31/5377 A61K31/55 A61P35/00 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of formula

wherein m is equal to 0, 1, 2; n is equal to 0, 1, 2, 3; each p, s, t is equal to 0 or 1; X represents CHR⁸ wherein R⁸ represents hydrogen; represents -CR⁹=C<, and then a dash line represents a bond, R⁹ independently represents hydrogen or C_1-6-alkyl, or wherein R⁹ together with one of R² or R²⁰ forms a direct bond; R¹ represents hydrogen; R² and R²⁰ are specified in: halogen, cyano, polyhalogen-C_1-6-alkyl, C_1-6-alkyl, morpholinyl, C_1-6-alkyloxy with any of said groups is optionally and independently substituted by hydroxy, NR²¹R²² wherein R²¹ and R²² are independently specified in hydrogen, C_1-6-alkylcarbonyl; or R² and R²⁰ together with a phenyl cycle whereto attached form a naphthaline group; or one of R² or R²⁰ have the values specified above, and the other of R² or R²⁰ together with R⁹ form a direct bond; R³ represents hydrogen; R⁴ and R⁵ independently represent hydrogen, C_1-6-alkyl, hydroxy-C_1-6-alkyl, C_2-6-alkenyl or C_1-6-alkyloxy; or R⁶ represents hydrogen; when p is equal to 1, then R⁷ represents hydrogen; Z represents one of the radicals presented in the patent claim. Also, the invention refers to a based pharmaceutical composition, using the compounds of formula (I) for producing the drug preparation for treating the disorders medicated by p53-MDM2 interaction for treating cancer, and to methods for producing the compounds of formula (I).

EFFECT: preparing the compounds of formula (I) as p53-MDM2 interaction inhibitors.

13 cl, 5 tbl, 31 ex